Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + carboplatin versus docetaxel + carboplatin as first-line treatment for advanced breast cancer
ChiCTR1900025258Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Sep 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Pemetrexed + carboplatin with Docetaxel + carboplatin (2 arms). Primary endpoint: Progression-free survival. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
pemetrexedcarboplatindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900025258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025258.